These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 11160777)

  • 41. Mechanism of action of thiazolidinediones.
    Flemmer M; Scott J
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1564-7. PubMed ID: 11763158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Thiazolidinediones].
    Scheen AJ; Paquot N; Letiexhe MR; Lefèbvre PJ
    Journ Annu Diabetol Hotel Dieu; 1999; ():213-29. PubMed ID: 10732419
    [No Abstract]   [Full Text] [Related]  

  • 43. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus.
    Bell DS
    Postgrad Med; 2003 May; Spec No():35-44. PubMed ID: 12785130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers.
    Hofmann CA; Colca JR
    Diabetes Care; 1992 Aug; 15(8):1075-8. PubMed ID: 1505314
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thiazolidinediones.
    Henry RR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):553-73. PubMed ID: 9314015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.
    Pathak R; Afaq A; Blonde L
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S483-94. PubMed ID: 12408411
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of thiazolidinediones on cardiovascular risk factors.
    Gouda BP; Asnani S; Fonseca VA
    Compr Ther; 2002; 28(4):200-6. PubMed ID: 12506489
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel insulin sensitizers: pharmacogenomic aspects.
    Otto C; Lehrke M; Göke B
    Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Insulin resistance syndrome. Description, pathogenesis, and management.
    Miller JL
    Postgrad Med; 2003 May; Spec No():27-34. PubMed ID: 12785129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
    Raji A; Plutzky J
    Curr Cardiol Rep; 2002 Nov; 4(6):514-21. PubMed ID: 12379175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The glitazones: proceed with caution.
    Krische D
    West J Med; 2000 Jul; 173(1):54-7. PubMed ID: 10903299
    [No Abstract]   [Full Text] [Related]  

  • 54. Insulin-sensitizing agents--thiazolidinediones (glitazones).
    Barnett AH
    Curr Med Res Opin; 2002; 18 Suppl 1():s31-9. PubMed ID: 12365817
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thiazolidinediones in the treatment of type 2 diabetes.
    Pittas AG; Greenberg AS
    Expert Opin Pharmacother; 2002 May; 3(5):529-40. PubMed ID: 11996632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
    Meriden T
    Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential new treatments for type 2 diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2000 Jul; 21(7):259-65. PubMed ID: 10871894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH; van Haeften TW
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
    Isshiki K; Haneda M; Koya D; Kikkawa R
    Nihon Rinsho; 2000 Feb; 58(2):440-5. PubMed ID: 10707573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.